Bilal Arshad Khan - 05 Feb 2026 Form 3 Insider Report for SpyGlass Pharma, Inc. (SGP)

Role: Director
Signature: /s/ Brian Aukshunas, as Attorney-in-Fact
Issuer symbol: SGP
Transactions as of: 05 Feb 2026
Net transactions value: $0
Form type: 3
Filing time: 05 Feb 2026, 13:06:29 UTC
Next filing: 11 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Khan Bilal Arshad	Director	C/O SPYGLASS PHARMA, INC., 27061 ALISO CREEK RD., SUITE 100, ALISO VIEJO	/s/ Brian Aukshunas, as Attorney-in-Fact	05 Feb 2026	0002108044

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SGP	Common Stock						5,450	05 Feb 2026	Direct
holding	SGP	Common Stock						136,427	05 Feb 2026	See footnote	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SGP	Stock Option (right to buy)							05 Feb 2026	Common Stock	11,992	$2.18	Direct	F2, F3
holding	SGP	Stock Option (right to buy)							05 Feb 2026	Common Stock	48,533	$7.11	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares held by New World Medical, Inc. (New World Medical). The Reporting Person is the Chief Executive Officer of New World Medical and as such has voting and investment control over the shares held by New World Medical.
F2	Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean September 20, 2023.
F3	Of the 100,000 shares subject to the option that were originally granted prior to a 5.7329 to 1 reverse stock split, 31,250 shares were exercised pre-reverse stock split and prior to the Reporting Person becoming a Section 16 director.
F4	Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean August 6, 2025.

Remarks:

Exhibit 24 - Power of Attorney